Elsevier updates major reference work, "Comprehensive Biomaterials II"

Detailed seven-volume work includes 75 percent new or updated articles, and is one of five new biomaterials titles


Cambridge, MA, June 8, 2017

Elsevier, the information analytics company specializing in science and health, today announced the second edition of Comprehensive Biomaterials II,  edited by Paul Ducheyne, Kevin Healy, Dietmar E. Hutmacher, David W. Grainger and C. James Kirkpatrick. One of five new biomaterials titles, this major reference work reviews the current status of nearly all biomaterials in the field by analyzing their strengths and weaknesses, performance, and future prospects.

The updated work covers all significant emerging technologies in areas such as 3D printing of tissues, organs and scaffolds, cell encapsulation, multimodal delivery, cancer/vaccine - biomaterial applications, neural interface understanding, materials used for in situ imaging, and infection prevention and treatment. With 75 percent new or revised articles, its seven volumes provide biomedical scientists in industry, government, academia and research organizations with an accessible and thoroughly accurate perspective on the field.

Learn more about silk biomaterials in this excerpt from Volume 2, also available in Elsevier’s Reference Module in Materials Science and Materials Engineering.

Dr. Ducheyne is Professor of Bioengineering at the University of Pennsylvania, Philadelphia, USA, and a member of the Institute for Medicine and Engineering (IME) and the Center for Engineering Cells and Regeneration (CECR). His research is focused in the investigation of mechanistic effects of materials on cellular functions, specifically cell attachment, proliferation, differentiation and extracellular matrix formation, especially with respect to biomaterials and tissue engineering.

Dr. Healy is the Jan Fandrianto Distinguished Professor in Engineering at the University of California at Berkeley in the Departments of Bioengineering and Materials Science and Engineering. His research interests include the design and synthesis of biomimetic materials that actively direct the fate of embryonic and adult stem cells, and facilitate regeneration of damaged tissues and organs.

Dr. Hutmacher is the Director of the Centre of Regenerative Medicine and Director of the Australian Research Council Centre in Additive Biomanufacturing at the Queensland University of Technology (QUT). He has expertise in biomaterials, biomedical engineering, and tissue engineering and regenerative medicine (TE&RM), and is also among the pioneers in the field of 3D printing in medicine.

Dr. Grainger is the George S. and Dolores Dore´ Eccles Presidential Endowed Chair in Pharmaceutics and Pharmaceutical Chemistry, and Chair and Professor of Bioengineering at the University of Utah, USA. His research focuses on improving implanted medical device performance, drug delivery of new therapeutic proteins, nucleic acids and live vaccines, nanomaterials interactions with human tissues, low-infection biomaterials, and innovating diagnostic devices based on DNA and protein biomarker capture.

Dr. Kirkpatrick is Senior Professor in the Cranio-Maxillofacial Surgery Clinic at the Goethe University of Frankfurt, and Visiting Professor of Biomaterials & Regenerative Medicine at the University of Gothenburg, Sweden. His principal research interests continue to be in the field of biomaterials in tissue engineering and regenerative medicine, with special focus on the development of human cell culture techniques, including novel 3D coculture methodology for biomaterials and the application of modern molecular pathology techniques to the study of biofunctionality of biomaterials, including nanomaterials.

The five new biomaterials titles are:

In order to meet content needs in biomaterials, Elsevier uses proprietary tools to identify the gaps in coverage of the topics. Editorial teams strategically fill those gaps with content written by key influencers in the field, giving students, faculty and researchers the content they need to answer challenging questions and improve outcomes. These new books, which will educate the next generation of biomaterials researchers and engineers, and provide critical foundational content for information professionals, are key examples of how Elsevier is enabling science to drive innovation.

---

Note for editors
Credentialed media can request eBook review copies by email, please contact sciencereviewcopies@elsevier.com

About Elsevier
Elsevier is a global information analytics business that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact
Pam Foote
Publicity Contact, Science & Technology Books, Elsevier
+1-978-837-8182
footep@reedelsevier.com